Balrampur Chini Mills Limited Financial Results for Year Ended March 2026

Balrampur Chini Mills Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated annual net profit of ₹37,846.34 lakh, supported by robust revenue from operations. Furthermore, the Board has approved the reappointment of key leadership, including Mr. Vivek Saraogi as Chairman and Managing Director, and Ms. Avantika Saraogi as Executive Director, reinforcing the company’s commitment to strategic leadership for the coming years.

Financial Highlights for FY2026

For the financial year ended March 31, 2026, Balrampur Chini Mills recorded a consolidated revenue from operations of ₹6,27,114.65 lakh. The net profit for the year stood at ₹37,846.34 lakh, reflecting the company’s strong operational performance across its diverse business segments, including sugar, distillery, and the innovative Polylactic Acid (PLA) project.

Strategic Leadership Reappointments

The Board of Directors has approved the reappointment of Mr. Vivek Saraogi as the Chairman and Managing Director for a 5-year term commencing April 1, 2027. Additionally, Ms. Avantika Saraogi has been reappointed as the Executive Director for a 5-year term starting January 1, 2027. These leadership decisions ensure continuity in the company’s vision and strategic direction.

Business Growth and Sustainability

The company continues to advance its sustainability initiatives, particularly through the ‘Balrampur Bioyug’ project, which focuses on manufacturing bio-plastics from sugarcane. This initiative has positioned the company as a key player in the green innovation sector. The Board has also approved the reappointment of M/s. Mani & Co. as the Cost Auditors for the 2026-27 financial year, ensuring continued transparency and operational compliance.

Preferential Issue Approval

To further support its growth trajectory, the Board has approved a preferential issuance of up to 93,16,771 equity shares at an issue price of ₹483 per share, aggregating to ₹45,000 lakh. This capital infusion will be directed toward strengthening the company’s financial position and funding future expansion plans.

Source: BSE

Previous Article

Alembic Pharmaceuticals API-III Facility Receives ANVISA Approval

Next Article

General Insurance Corporation of India Leadership Change in Finance Department